注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （文章来源：证券时报网） | 代码 | 简称 | 每股收益 | 净利润（万 | 净利润同比 | 营业收入（万 | 营业收入同比 | | --- | --- | --- | --- | --- | --- | --- | | | | （元） | 元） | （%） | 元） | （%） | | 301120 | 新特电 气 | 0.0100 | 532.87 | 49775.01 | 19265.03 | 16.10 | | 301258 | 富士莱 | 0.4744 | 4307.66 | 12430.96 | 22390.97 | 3.36 | | 300046 | 台基股 | 0.1680 | 3972.84 | 3789.41 | 17878.78 | 4.18 | | | 份 | | | | | | | 300079 | 数码视 讯 | 0.0117 | 1670.03 | 2747.64 | 26484.56 | 24.66 | | 603086 | 先达股 份 | 0.3100 | 13603.97 | 2561.58 | 142261. ...

3）*ST铖昌 （正圆投资参与公司特定对象调研） 调研纪要：报告期内，下游用户需求恢复加快，公司在手订单及项目显著增加。公司部分遥感星载项目 将于2024年进入小批阶段，2025年进入批产阶段，增速可观。公司在星载、低轨卫星、机载和地面领域 均取得进展，订单充足，产能提升。公司综合毛利率稳定，通过提高研发效率和优化生产工艺降低成 本，有信心保持合理毛利率。项目周期因应用场景不同而异，随着需求增加，平均项目周期逐渐缩短， 验收节奏加快。公司在低轨卫星领域有技术优势，已为下一代低轨通信卫星备货并批量交付，该领域将 成为新的增长点。公司通过前瞻性技术布局，积极拓展低空经济等多场景应用，解决低空探测盲区问 题。T/R芯片行业存在高技术壁垒，公司具有技术先发优势和丰富经验，竞争格局以科研院所和少数民 营企业为主。 机构简介： 根据市场公开信息及8月21日披露的机构调研信息，知名私募正圆投资近期对3家上市公司进行了调研， 相关名单如下： 1）利民股份 （正圆投资参与公司特定对象调研） 调研纪要：2025年上半年，利民股份销售收入24.52亿元，同比增长6.69%；净利润2.69亿元，同比增长 747.13%。业绩改善主要 ...

利民股份8月21日大宗交易平台共发生17笔成交，合计成交量371.52万股，成交金额7066.30万元。成交 价格均为19.02元，相对今日收盘价折价11.20%。从参与大宗交易营业部来看，机构专用席位共出现在8 笔成交的买方或卖方营业部中，合计成交金额为4559.47万元，净买入4559.47万元。 进一步统计，近3个月内该股累计发生23笔大宗交易，合计成交金额为8631.31万元。 证券时报·数据宝统计显示，利民股份今日收盘价为21.42元，上涨2.49%，日换手率为14.66%，成交额 为12.53亿元，全天主力资金净流入6386.28万元，近5日该股累计下跌1.06%，近5日资金合计净流出3.70 亿元。 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （文章来源：证券时报网） 两融数据显示，该股最新融资余额为4.79亿元，近5日减少1.26亿元，降幅为20.88%。（数据宝） 8月21日利民股份大宗交易一览 | 成交量 | 成交金 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | 额（万 | 格 | 折溢 ...

| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | 2025-08-21 | 002734 | 利民股份 | 19.02 | 20.00 | 380.40 招商证券股份有限 | 华西证券股份有限 | | | | | | | 公司西安北大街证 | 公司苏州分公司 | | | | | | | 券营业部 | | | 2025-08-21 | 002734 | 利民股份 | 19.02 | 42.00 | 798.84 机构专用 | 华西证券股份有限 | | | | | | | | 公司苏州分公司 | | 2025-08-21 | 002734 | 利民股份 | 19.02 | 10.60 | 201.61 机构专用 | 国金证券股份有限 | | | | | | | | 公司上海静安区南 | | | | | | | | 京西路证券营业部 | | 2025-08-21 | 002734 | 利民股份 | ...

Group 1: Market Performance - The agricultural chemical sector rose by 1.36% on August 21, with Meibang Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3771.1, up 0.13%, while the Shenzhen Component Index closed at 11919.76, down 0.06% [1] Group 2: Individual Stock Performance - Meibang Co., Ltd. (code: 605033) closed at 23.77, with a 10.00% increase and a trading volume of 122,900 shares, amounting to a transaction value of 283 million [1] - Hong Sifang (code: 603395) closed at 36.46, up 6.36%, with a trading volume of 156,100 shares [1] - New Yangfeng (code: 000902) closed at 15.21, up 6.29%, with a trading volume of 684,200 shares, totaling 1.035 billion [1] - Other notable performers include Stanley (code: 002588) with a 5.40% increase and Yangnong Chemical (code: 600486) with a 5.33% increase [1] Group 3: Fund Flow Analysis - The agricultural chemical sector experienced a net outflow of 10.82 million from institutional investors, while retail investors saw a net outflow of 60.06 million [2] - The sector attracted a net inflow of 70.88 million from speculative funds [2] Group 4: Detailed Fund Flow for Selected Stocks - Limin Co., Ltd. (code: 002734) had a net inflow of 1.29 billion from institutional investors, but a net outflow of 1.34 billion from retail investors [3] - Yun Tianhua (code: 600096) saw a net inflow of 99.11 million from institutional investors, with a net outflow of 1.17 billion from retail investors [3] - Meibang Co., Ltd. (code: 605033) had a net inflow of 69.47 million from institutional investors, but a significant net outflow from both speculative and retail investors [3]

格隆汇8月21日｜国海证券研报指出，利民股份上半年实现归母净利润2.69亿元，同比增长747.13%； Q2实现归母净利润1.61亿元，同比增长299.54%，环比增长48.66%。核心产品量价齐升，2025H1公司业 绩同比+747%。公司进一步巩固国内杀菌剂龙头的地位，推动技术创新、全球化布局和绿色转型，持续 扩大市场份额，主要产品价格和销量同比上涨、毛利率提升。2025年上半年，公司技术研发支撑力不断 增强，化学合成创制计划稳步推进，与巴斯夫的创新药开发合作进展顺利，产品规划梯次形成，配方研 究水平不断提高，生物合成的研究方向扎实开展。下半年进入南美市场销售旺季，预计杀菌剂产品代森 锰锌、百菌清的市场需求支撑将带来景气持续上行。维持"买入"评级。 ...

Financial Performance - In the first half of 2025, the company achieved a sales revenue of CNY 2.452 billion, a year-on-year increase of 6.69% [3] - Net profit reached CNY 269 million, reflecting a significant year-on-year growth of 747.13% [3] - The gross profit margin was 26.13%, up by 8.11% compared to the previous year [3] - Accounts receivable decreased by 8.01% to CNY 599 million [3] - The debt-to-asset ratio improved to 47.78%, down by 11.75% year-on-year [3] Key Drivers of Performance - Core products saw both volume and price increases, with strong market demand for key products such as Mancozeb, Chlorothalonil, Abamectin, and Methomyl [3] - The "Safety Cushion Resilience Plan" effectively controlled costs and improved efficiency through optimized production processes and supply chain management [4] - Successful expansion into overseas markets, particularly in Brazil, where the company obtained several product registrations [4] - Enhanced capacity utilization and operational efficiency due to improved market conditions and internal management [4] Product Contribution - The agricultural pesticide segment generated CNY 2.199 billion in revenue, a 4.63% increase year-on-year, with a gross margin of 26.45% [6] - The veterinary medicine segment reported revenue of CNY 229 million, a growth of 27.73% year-on-year, with a gross margin of 21.66% [6] - Specific product performance included: - Agricultural fungicides: CNY 1.240 billion in revenue, gross margin of 33.77% [6] - Agricultural insecticides: CNY 748 million in revenue, gross margin of 24.32% [6] - Agricultural herbicides: CNY 208 million in revenue, with a decrease in gross margin by 7.47% [6] Investment and Market Outlook - Investment income increased significantly, primarily from the investment in Jiangsu Xinhai Agricultural Chemical Co., Ltd. [7] - The price of Mancozeb has risen approximately 20% since January 2025, with strong demand in Brazil, where the product is crucial for soybean disease management [8] - The company expects continued growth in demand for Mancozeb, with import volumes in Brazil nearly doubling in 2024 to 88,000 tons [8] Strategic Initiatives - The company is focusing on enhancing brand influence and expanding overseas operations, with significant revenue from Brazil (CNY 200 million) and the U.S. (over CNY 70 million) in the first half of 2025 [11] - The implementation of the "One Certificate, One Product" policy is anticipated to benefit the company due to its extensive registration resources [12] - Future plans include improving production quality, expanding market presence, and enhancing technological innovation [18]

Group 1: Key Insights on Xtep International - The main brand performance is stable, with significant growth in the professional sports segment, achieving a total revenue of 6.84 billion yuan in H1 2025, a year-on-year increase of 7.1% [3][4] - The professional sports revenue increased by 32.5% to 785 million yuan, contributing to a notable improvement in operating profit margin, which rose by 6.1 percentage points to 10% [4][5] - The company maintains a strong cash position, with net cash increasing by 94.3% to 1.913 billion yuan, indicating stable overall operations [5][6] Group 2: Key Insights on Meitu Inc. - Meitu Inc. reported a revenue of 1.82 billion yuan in H1 2025, reflecting a year-on-year growth of 12.3%, with a gross profit of 1.34 billion yuan and a gross margin of 73.6% [8][9] - The revenue from AI-driven imaging and design products grew by 45.2% to 1.35 billion yuan, driven by an increase in active user base and payment penetration [10] - The company is successfully advancing its globalization strategy, with a 15% year-on-year increase in monthly active users outside mainland China [10] Group 3: Key Insights on Wavelength Optoelectronics - Wavelength Optoelectronics achieved a revenue of 220 million yuan in H1 2025, a year-on-year increase of 17.8%, although net profit decreased by 50.6% to 14 million yuan [12][13] - The company is focusing on the semiconductor and optoelectronic markets, with a significant revenue increase of 99% in semiconductor-related products [14] - The company is expanding its consumer optical products, with AR/VR optical product revenue increasing by 470% [14] Group 4: Key Insights on Dongfang Wealth - Dongfang Wealth reported a total revenue of 6.856 billion yuan in H1 2025, a year-on-year increase of 38.65%, with net profit growing by 35.38% [16][17] - The brokerage and margin financing businesses are the main growth drivers, benefiting from a significant market recovery with a daily average trading volume increase of 61% [17][18] - The company has a solid traffic foundation, with its brokerage, margin financing, and fund distribution businesses showing strong resilience [18] Group 5: Key Insights on Zhongke Feicai - Zhongke Feicai achieved a revenue of 700 million yuan in H1 2025, reflecting a year-on-year growth of 51.4%, with a gross margin of 54.3% [22][23] - The company is expanding its order scale, with inventory and contract liabilities increasing, indicating a positive future performance trend [23][24] - The company is focusing on the development of seven series of equipment, with steady growth in market share for its detection devices [25] Group 6: Key Insights on Tongcheng Travel - Tongcheng Travel reported a revenue of 4.7 billion yuan in Q2 2025, a year-on-year increase of 10%, with adjusted net profit rising by 18% [26][27] - The core online travel platform showed robust growth, with a revenue increase of 14% in transportation ticketing and 15% in accommodation bookings [27][28] - The company is focusing on expanding its user base in lower-tier cities, with a significant portion of new paid users coming from these regions [28] Group 7: Key Insights on Limin Co. - Limin Co. achieved a revenue of 2.452 billion yuan in H1 2025, with a remarkable net profit increase of 747.13% [30][31] - The company is consolidating its position as a leading pesticide manufacturer, with significant price and sales increases for its main products [32][34] - The company is advancing its research and development capabilities, with ongoing collaborations for innovative product development [34][35]

Investment Rating - The report maintains an "Outperform" rating for the chemical industry [2] Core Insights - The chemical industry is expected to benefit from anti-involution policies aimed at curbing disorderly competition and eliminating outdated production capacity, which may lead to a recovery in industrial product prices and positively impact PPI and CPI [6][11][17] - The report highlights the significant influence of the energy and chemical sectors on PPI, with their price fluctuations directly affecting overall industrial inflation levels [16] - The industry is under pressure from declining product prices and reduced capacity utilization, leading to a strong demand for anti-involution measures [17] - The current valuation of the chemical industry is at a historical low, providing substantial upside potential as the sector is expected to recover from its cyclical bottom [17][19] Summary by Sections 1. Importance of Inflation Recovery - The report emphasizes that the chemical sector is a crucial lever for inflation recovery, as evidenced by the PPI's continuous decline and the need for policy intervention to combat deflationary pressures [6][11] 2. Reasons to Focus on Chemicals - The energy and chemical sectors account for 25%-30% of PPI, making their price recovery vital for overall inflation [16] - The industry faces significant profitability challenges, with nearly 25% of chemical companies reporting losses in 2024 [17] 3. Paths for Anti-Involution in Chemicals 3.1. Active Approach: Industry Self-Regulation - Certain sub-industries, such as polyester filament and sucralose, are attempting to improve profitability through supply-side collaboration, benefiting from high concentration and low profitability [27][29] - The report identifies key chemical products likely to benefit from self-regulation, including polyester filament, polyester bottle chips, and organic silicon [29][31] 3.2. Passive Approach: Policy-Driven Industry Improvement - The report outlines a dual-track policy framework focusing on optimizing existing capacity and strictly controlling new projects to enhance the competitive landscape [27][31] - Historical experiences suggest that effective policy measures will include phasing out outdated facilities and enforcing stricter environmental regulations [27][31]

Group 1 - On August 20, Limin Co., Ltd. executed a block trade of 108,000 shares, with a transaction value of 2.0596 million yuan, accounting for 0.36% of the total transaction volume for the day [1][2] - The transaction price was 19.07 yuan, which represents an 8.76% discount compared to the market closing price of 20.9 yuan [1][2]